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Abstract
Background: The implementation of gene therapy for the treatment of pituitary tumors emerges
as a promising complement to surgery and may have distinct advantages over radiotherapy for this
type of tumors. Up to now, suicide gene therapy has been the main experimental approach
explored to treat experimental pituitary tumors. In the present study we assessed the effectiveness
of insulin-like growth factor I (IGF-I) gene therapy for the treatment of estrogen-induced
prolactinomas in rats.
Results: Female Sprague Dawley rats were subcutaneously implanted with silastic capsules filled
with 17-β estradiol (E2) in order to induce pituitary prolactinomas. Blood samples were taken at
regular intervals in order to measure serum prolactin (PRL). As expected, serum PRL increased
progressively and 23 days after implanting the E2 capsules (Experimental day 0), circulating PRL had
undergone a 3–4 fold increase. On Experimental day 0 part of the E2-implanted animals received a
bilateral intrapituitary injection of either an adenoviral vector expressing the gene for rat IGF-I
(RAd-IGFI), or a vector (RAd-GFP) expressing the gene for green fluorescent protein (GFP). Seven
days post vector injection all animals were sacrificed and their pituitaries morphometrically
analyzed to evaluate changes in the lactotroph population. RAd-IGFI but not RAd-GFP, induced a
significant fall in serum PRL. Furthermore, RAd-IGFI but not RAd-GFP significantly reversed the
increase in lactotroph size (CS) and volume density (VD) induced by E2 treatment.
Conclusion: We conclude that IGF-I gene therapy constitutes a potentially useful intervention for
the treatment of prolactinomas and that bioactive peptide gene delivery may open novel
therapeutic avenues for the treatment of pituitary tumors.
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Pituitary adenomas constitute the most frequent neuroen-
docrine pathology in humans, comprising up to 15% of
primary intracranial tumors [1] and also are the most
prevalent pathology in old female rats [2]. In both species,
prolactinomas are the most frequent type of pituitary ade-
noma.
Estrogen exposure has been linked to the formation of
prolactinomas in both humans and animals [3-5]. Estro-
gens, particularly estradiol and diethylstilbestrol, have
been shown to induce lactotropic cell tumors within 2–4
weeks in female rats. Women taking oral contraceptives
often display increased prolactin (PRL) levels and have
increased incidence of prolactinomas, although not all
women appear to be equally susceptible to the mitogenic
effect of estradiol [6,7].
There are a number of growth factors that are estrogen-
dependent and function in lactotropic proliferation, dif-
ferentiation, and/or transformation. The relatedness of
these factors and the significance of each alone are not
well-understood. Some of these estrogen-regulated factors
are epidermal growth factor (EGF), platelet-derived
growth factor (PDGF), transforming growth factor alpha
(TGF-α), basic fibroblast growth factor (bFGF), inter-
leukin-2 (IL-2), IL-6, fibroblast growth factor-4 (FGF-4),
transforming growth factor-β (TGF-β), insulin-like growth
factor-I (IGF-I) and IGFI-II [8,9]. Although estrogen is
known to up-regulate IGF-I mRNA in normal rat pituitar-
ies [10], large estrogen-induced pituitary adenomas have
been reported to possess decreased levels of IGF-I mRNA.
Furthermore, partial remission induced by the anti-estro-
gen tamoxifen was associated with an increase in the pitu-
itary content of IGF-I mRNA of these adenomas [11].
Also, it has been shown that in primary cultures of rat lac-
totrophs, estrogen has an antiproliferative action in the
presence of insulin or IGF-I [12,13]. In view of this evi-
dence, it was of interest to determine whether in vivo over-
expression of the gene for rat IGF-I in estrogen-induced rat
prolactinomas could be able to restore lacotropic cell
morphology and reverse hyperprolactinemia. The present
report describes our findings.
Results
Effect of IGF-I gene therapy on pituitary lactotroph 
morphology
Stereotaxic injection of RAd-GFP (an adenoviral vector
expressing a chimeric variant of green fluorescent protein;
see Methods) into pituitary adenomas induced a signifi-
cant expression of GFP around the track of the needle (Fig.
1) without significantly damaging the gland (Fig. 1, inset).
As expected, three weeks of estrogen treatment induced a
significant increase in pituitary size (data not shown) as
well as clear changes in the lactotropic cell population,
already evident when pituitary sections were qualitatively
assessed (Fig 2). Estrogen-induced pituitary adenomas
showed a significant (p < 0.01) increase in lactotropic cell
size as compared with their intact counterparts (Fig. 3;
also see Fig. 2). Seven days of IGF-I gene therapy signifi-
cantly reversed this change (p < 0.01) although lactotroph
cell surface (CS) was still higher than in intact animals
(Fig. 3; also see Fig. 2). Lactotroph volume density (VD)
was higher in estrogen-induced pituitary adenomas when
compared with the pituitaries of intact animals (Fig. 4).
Again, IGF-I gene therapy significantly (p < 0.05) reversed
this alteration although lactotroph VD in RAd-IGF-I
injected adenomas remained higher than in normal intact
glands (Fig. 4).
Effect of intrapituitary tumor IGF-I gene therapy on serum 
PRL levels
As expected, estrogen administration induced a marked
hyperprolactinemia in the animals. Seven days after stere-
otaxic intrapituitary injection of RAd-IGF-I but not RAd-
GFP, a significant fall in serum PRL occurred in the estro-
gen-treated rats (Fig. 5). Nevertheless, serum PRL of the
RAd-IGF-I-treated rats remained higher than in the intact
rats.
Discussion
Current therapies for pituitary tumors include surgery and
radiotherapy, as well as pharmacological approaches for
some types and, although important advances have been
made in the treatment of pituitary tumors with these strat-
egies, a fully satisfactory therapy is not yet available [14].
In this context, gene therapy appears as a potentially use-
ful alternative for the treatment of pituitary tumors.
Early studies showed that a herpes simplex virus type-1
(HSV1)-derived vector was highly effective in vivo for gene
transfer in rat pituitary prolactinomas [15]. An adenoviral
vector, RadTK, harboring the HSV-1 thymidine kinase
(TK) suicide gene under the control of the human cytome-
galovirus (hCMV) promoter, was used to transfer the TK
gene to GH3 and AtT20 rodent pituitary tumor cells. Incu-
bation of RadTK-treated GH3 and AtT20 cells with the pro-
drug ganciclovir (which after phosphorylation by viral TK
becomes toxic) caused ample destruction of the cultures
[16]. In the same study, estrogen/sulpiride-induced rat
prolactinomas were stereotaxically injected with the same
RadTK. Subsequent injection of the host animals with two
daily intrapituitary doses of 25 mg ganciclovir/kg for 7
days succeeded in partially reducing tumor size and serum
PRL levels. Another type of gene therapy strategy for the
treatment of pituitary cancer is that based on the transfer
of a gene(s) with the ability to rescue the normal pheno-
type of tumor cells. This approach has been implemented
in mice heterozygous for the retinoblastoma (RB) tumor
suppressor gene (Rb+/- mice) which develop and succumbPage 2 of 7
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tumors [17]. Intracranial delivery of an adenoviral vector
harboring the human RB cDNA to mice carrying actively
growing melanotrophic tumors significantly reduced
tumor growth and prolonged animal survival [18].
The present study is the first to implement effective pitui-
tary tumor gene therapy using the gene for a bioactive
peptide. Within the time frame used, the treatment seems
to act mainly on PRL cell size and secretory activity rather
than on PRL cell density (CD, data not shown). Our
results are consistent with the above mentioned reports
documenting that large estrogen-induced pituitary adeno-
mas possess decreased pituitary levels of IGF-I mRNA and
that the anti-estrogen tamoxifen increased the IGF-I
mRNA content in the involuting adenomas [11]. Our
results are also consistent with the evidence that in rat lac-
totrophs, estrogen has an antiproliferative action in the
presence of insulin or IGF-I [12,13]. Furthermore, our
data showing that IGF-I gene therapy reduces PRL secre-
tion in estrogen-induced prolactinomas are in line with
an early study in rat pituitary cells reporting that IGF-I
inhibited the estrogen induced rise in PRL and lactotroph
pituitary transcription factor-1 (Pit-1) mRNA levels in
females. This study also documented that the inhibitory
effect of IGF-I on estrogen-induced PRL and lactotroph
Pit-1 mRNA levels did not occur in male pituitary cells
[19].
The mechanism by which pituitary overexpression of IGF-
I reduces lactotropic cell size and inhibits PRL secretion is
not clear. Although estrogen is known to increase pituitary
expression of IGF-I mRNA, it also increases the expression
of IGF binding protein 2 (IGF-BP2) mRNA [10]. Since our
approach involves pituitary overexpression of transgenic
IGF-I, probably not paralleled by a concomitant increase
in IGF-BP2, the possibility exists that high levels of free
IGF-I exert an inhibitory action on the lactotrophs. It is
well-established that IGF-I exerts a potent negative feed-
back on somatotropic cells [20-22]. Since lactotrophs and
somatotrophs have a common origin and share a number
of physiologic features, it seems conceivable that high
pituitary concentrations of free IGF-I could have an inhib-
itory action on lactotropic cells. Clearly, further work is
necessary to clarify this matter.
Expression of transgenic GFP/TK in a pituitary adenomaFigure 1
Expression of transgenic GFP/TK in a pituitary adenoma. The main panel shows the green fluorescence of transduced 
cells around the entry point (arrow) of the needle used to stereotaxically deliver RAd-GFP/TK into the tumor Obj. ×20. The 
inset shows a low magnification view of the same pituitary adenoma where an entry point of the needle can be seen (arrow). 
No structural damage is evident as a consequence of the injection. Obj. ×4.Page 3 of 7
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tially useful intervention for the treatment of prolactino-
mas and that bioactive peptide gene delivery may open
novel therapeutic avenues for the treatment of pituitary
tumors.
Methods
Adenoviral vectors
RAd-IGFI
A recombinant adenoviral (RAd) vector harboring the rat
IGF-I gene (kindly donated by Dr. Peter Rotwein, Oregon
Health Sciences University) was constructed in our labo-
ratory by a variant of the two plasmid method employing
the AdMax® plasmid kit (Microbix, Ontario, Canada) [23].
Briefly, the cDNA coding for rat IGF-I gene (obtained from
the mRNA for the IGF Ib precursor form [24]) was excised
from plasmid pBluescript KS, subcloned in pCA14 and
inserted in the multiple cloning site (MCS) of shuttle
pDC515 which contains an expression cassette consisting
of the mouse cytomegalovirus promoter (mCMV) and the
simian virus 40 (SV40) polyadenylation signal, immedi-
ately upstream and downstream to the MCS, respectively.
The second plasmid of the kit, the genomic plasmid pBH-
Gfrt(del)E1,3 FLP, consists of the entire genome of aden-
ovirus 5 (Ad5), containing deletions in the regions E1 and
E3. In cotransfected HEK293 cells, FLP recombinase is
readily expressed and efficiently catalyzes the site-directed
recombination of the expression cassette of pDC515 into
pBHGfrt(del)E1,3 FLP, thus generating the genome of the
desired recombinant adenoviral vector, RAd-IGF-I (Fig.
Effect of IGF-I gene therapy on lactotropic cells of pituitary adenomasFigure 2
Effect of IGF-I gene therapy on lactotropic cells of pituitary adenomas. Representative fields of specifically immunos-
tained PRL-cells in the pituitary gland of an intact (Intact) rat, an animal treated with estrogen for 4 weeks (E only), and animal 
receiving estrogen for 4 weeks and RAd-GFP during the last experimental week (E + RAdGFP) and an animal receiving estro-
gen for 4 weeks and RAd-IGF-I during the last experimental week (E + RAd-IGF-I). Insets. Higher magnification views of the 
specimens. EnVision system peroxidase. Bar: 25 µm. Inset: 12.5 µm.Page 4 of 7
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cell lysates and plaque purified. It was further purified by
ultracentrifugation in CsCl gradient. Final virus stocks
were titrated by a serial dilution plaque assay.
RAd-(GFP/TK)fus
An adenoviral vector termed RAd-(GFP/TK)fus, or RAd-
GFP for short, was constructed in our laboratory following
the general procedures outlined above and was used as a
control vector in the gene therapy studies. The vector har-
bors a hybrid gene encoding the Aequorea victoria
enhanced green fluorescent protein fused to herpes sim-
plex virus type 1 thymidine kinase (GFP/TK)fus (a kind
gift from Dr. Jacques Galipeau, McGill University, Mon-
treal, Canada). This hybrid gene is driven by the mouse
CMV promoter. The vector was expanded in 293 cells and
purified and titrated as indicated above.
Animals
Young female Sprague-Dawley rats were housed in a tem-
perature-controlled room (22 ± 2°C) on a 12:12 h light/
dark cycle. Food and water were available ad libitum. All
experiments with animals were done following the Ani-
mal Welfare Guidelines of NIH (INIBIOLP's Animal Wel-
fare Assurance No A5647-01).
Experimental design for in vivo IGF-I gene therapy
At experimental day -23 all animals but those of the intact
group, were subcutaneously implanted a silastic capsule
filled with 17-β estradiol. Small blood samples (0.4 ml)
were taken from the tail veins of all rats on experimental
day -16, -9, 0, day +2 and day +7 for PRL assay. On exper-
imental day 0, some of the rats received bilateral 1.5 µl
intrapituitary injections containing 3 × 109 plaque form-
ing units (pfu) of either RAd-GFP or RAd-IGF-I, respec-
Effect of IGF-I gene therapy on serum PRL levelsFigure 5
Effect of IGF-I gene therapy on serum PRL levels. 
Serum PRL was measured in blood samples serially taken 
from Experimental day -23 to Experimental day 7. The 
number of rats used was 5 for all groups except for group E2 
+ RAd-IGF-I where 7 animals were assessed Asterisks indi-
cate significant differences from serum PRL on experimental 
day 0 (vector injection); *: P < 0.05; **: P < 0.01. Other 
details are as in Fig. 3
Effect of IGF-I gene therapy on lactotropic cell sizeFigure 3
Effect of IGF-I gene therapy on lactotropic cell size. 
Lactotroph cell surface (CS) in the pituitaries of animals sub-
mitted to no treatment (intact), control treatments (E2 only 
and E2 + RAdGFP) or IGF-I gene therapy (E2 + RAd-IGF-I). 
Columns represent mean values whereas bars over columns 
represent SEM values. Five pituitaries per group were 
assessed. Asterisks indicate a highly significant difference 
from the intact group.
Effect of IGF-I gene therapy on lactotropic volume density (VD)Figure 4
Effect of IGF-I gene therapy on lactotropic volume 
density (VD). Data correspond to the pituitaries of the 
same animals shown in Fig 3. Details are as in Fig. 3.Page 5 of 7
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injection of ketamine hydrochloride (40 mg/kg, i.p.) and
xylazine (8 mg/kg, i.m.), and placed in a stereotaxic frame.
In order to access the pituitary region, the tip of a 26 gauge
needle fitted to a 10 µl syringe was brought to the follow-
ing coordinates relative to the bregma: 5.5 mm posterior,
9.6 mm ventral and 0.7 mm right and left [25]. One week
after intrapituitary injection rats were killed by decapita-
tion. Pituitaries were immediately dissected, fixed and
processed for routine histological studies.
Immunohistochemistry
Stated in brief, pituitary tissues from 5 animals of each
group were fixed in Bouin's fluid and embedded in paraf-
fin. Serial sections of 4 µm were obtained at different lev-
els of the blocks following a ventral-to-dorsal sequence.
The sections were immunostained, and then incubated
for 1 h at room temperature with the anti-PRL primary
antiserum (murine, Dako, CA, USA), diluted 1:100. Thor-
oughly washed sections were then treated for 30 min with
a ready-to-use EnVision reaction system (Dako, CA, USA).
The peroxide-sensitive chromogen was diaminobenzi-
dine. In all instances, the specificity of the primary antise-
rum was monitored either by observing its ability to block
the immunocytochemical reaction after its preabsorption
with an excess of the related antigen or by its replacement
with normal rabbit serum or phosphate-buffered saline
[26].
Image analysis
Morphometry was performed as reported in detail previ-
ously [27]. Measurements of pituitary cells were made by
means of an image-analysis system (Imaging Technology,
Optimas 5.2). The immunostained lactotrope cells and
the reference area (RA) were analyzed in each field on an
average of ten micrographs taken from two levels (e.g. a
and b) in the groups studied. These measurements were
recorded and processed automatically and the following
parameters subsequently calculated: volume density (VD
= Σ cell area/RA) and cell size (CS) (the mean of individ-
ual cell area, expressed in µm2). Reference area (RA) rep-
resents the adenohypophyseal (pars distalis) area scanned,
in which pituitary PRL cells were scored. Then, with the
sum (Σ) of the individual areas (A), referred to as RA, we
obtained volume density (VD), which indicates cell mass
according to a generally accepted concept.
Hormone assays
Serum levels of PRL were measured by a specific radioim-
munoassay using the rat materials provided by Dr. A. F.
Parlow, Pituitary Hormones and Antisera Center, UCLA
Med. Center, U.S.A. Iodination grade hormones were
radiolabeled by the Iodo-Gen® method and purified on
PD-10 Sephadex® G-25 M columns (Pharmacia, Uppsala,
Sweden) equilibrated with 0.01 M phosphosaline, pH
7.6. A 1/10 goat anti-rabbit IgG in 0.9% NaCl was used to
separate bound from free hormone. Serum concentra-
tions of PRL were expressed in terms of NHPP rPRL RP-3.
Statistical analysis
The one way analysis of variance (ANOVA) were used to
evaluate group differences. Tukey's method was chosen as
a post hoc test. In Figs. 3 and 4 pair comparisons were
made between intact and each of the other experimental
groups. Also, RAd-GFP vs. RAd-IGF1 pairs were compared
in both figures. In Fig. 5 one-way ANOVA was applied to
each set of data (intact, E2, etc) and pair comparisons
were made between Exptl. Day 0 and each of the other
time points.
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Diagrammatic representation of the procedure used to con-struct RAd-IGF-IFigure 6
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moter (PmCMV) and the SV40 polyadenylation signal 
(SV40pA), upstream and downstream, respectively, was 
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(which consists of the entire genome of adenovirus 5 (Ad 5), 
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